Intellia Therapeutics (NTLA) – Investment Analysts’ Recent Ratings Updates

Intellia Therapeutics (NASDAQ: NTLA) has recently received a number of price target changes and ratings updates:

• 1/27/2025 – Intellia Therapeutics was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $11.00 price target on the stock, down previously from $56.00.
• 1/14/2025 – Intellia Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $19.00 to $12.00. They now have a “neutral” rating on the stock.
• 1/13/2025 – Intellia Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $60.00 to $40.00. They now have an “outperform” rating on the stock.
• 1/10/2025 – Intellia Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $70.00 to $60.00. They now have an “overweight” rating on the stock.
• 1/10/2025 – Intellia Therapeutics had its price target lowered by analysts at BMO Capital Markets from $70.00 to $50.00. They now have an “outperform” rating on the stock.
• 1/10/2025 – Intellia Therapeutics had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, down previously from $14.00.

Intellia Therapeutics Stock Up 0.1 %

NASDAQ NTLA opened at $10.02 on Wednesday. Intellia Therapeutics, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $34.87. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -1.84 and a beta of 1.83. The business has a fifty day moving average of $12.47 and a 200-day moving average of $17.83.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. During the same period last year, the firm earned ($1.38) earnings per share. The business’s revenue was down 24.1% compared to the same quarter last year. As a group, analysts anticipate that Intellia Therapeutics, Inc. will post -5.09 EPS for the current year.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders have sold 28,735 shares of company stock worth $349,909. 3.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the stock. Eastern Bank bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $41,000. Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $54,000. KBC Group NV lifted its holdings in shares of Intellia Therapeutics by 62.4% in the 4th quarter. KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after purchasing an additional 2,340 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after acquiring an additional 794 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in Intellia Therapeutics by 182.7% during the 3rd quarter. Blue Trust Inc. now owns 4,189 shares of the company’s stock valued at $94,000 after acquiring an additional 2,707 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.